|| List of recent Vaccine-related patents
| Hiv protease inhibitors|
The compounds encompassed by formula i include compounds which are hiv protease inhibitors and other compounds which can be metabolized in vivo to hiv protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by hiv and the prophylaxis, treatment, or delay in the onset of aids.
| Compositions and methods to immunize against hepatitis c virus|
Compositions comprising viral antigens and antigenic peptides corresponding to or derived from hepatitis c virus (hcv) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (dcs) are described herein. Included herein are immunostimulatory compositions (hcv vaccines, hcv antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of hcv antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis c in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis c..
| Immunotherapeutic methods using epitopes of wt-1 and gata-1|
A peptide comprising the amino acid sequence rmfpnapyl or a portion or variant thereof provided that the peptide is not intact human wt-1 polypeptide or a peptide comprising the amino acid sequence cmtwnqmnl or a portion or variant thereof provided that the peptide is not intact human wt-1 polypeptide or a peptide comprising the amino acid sequence hlmpfpgpll or a portion or variant thereof provided that the peptide is not intact human gata-1 polypeptide, and polynucleotides encoding these peptides. The peptides and polynucleotides are useful as cancer vaccines..
| Influenza b viruses having alterations in the hemaglutinin polypeptide|
The present invention encompasses methods of producing influenza b viruses in cell culture. The influenza b viruses may have desirable characteristics, such as enhanced replication in eggs and may be used, for example, in vaccines and in methods of treatment to protect against influenza b virus infection..
| Immunostimulatory oligodeoxynucleotides|
The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease, to methods for the detection of such oligodeoxynucleotides and to cells to be used in these methods.. .
| Vaccines for protection from and treatment of alzheimer's disease|
Disclosed herein are dna-based vaccines against amyloid β peptide for use in treating and alleviating alzheimer's disease and related conditions. A dna construct comprising dna encoding one or more amyloid β peptides, such as amino acids 1-11 of aβ, and dna encoding a hepatitis b antigens, is administered with an adjuvant or by electroporation.
| Influenza h5 vaccines|
The present invention is based on the surprising finding that h5 protein of clade 1 h5n1 induces, in particular by a single-shot vaccination, a cross-clade protective immune response to influenza viruses with h5n1 ha. In one aspect, the invention is thus directed to h5 protein of clade 1 h5n1 virus for use in a method of treating or preventing infections with h5n1 virus of a different clade, namely of a clade different from clade 1 or from any clade with the exception of clade 1, respectively..
| Tmem22 peptides and vaccines including the same|
Isolated peptides composed of the amino acid sequence of seq id no: 33 or fragments thereof that bind to hla antigens and have cytotoxic t lymphocyte (ctl) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic t cell inducibility.
| C1orf59 peptides and vaccines including the same|
The present invention provides isolated peptides having the amino acid sequence of seq id no: 43 or immunologically active fragments thereof, which bind to hla antigen and have cytotoxic t lymphocyte (ctl) inducibility. The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic t cell inducibility.
| Compositions comprising agents that inhibit neuropilin and tolloid like 2|
We disclose agents that inhibit the expression of neto-2 which has elevated expression in cancer stem cells; the use of neto-2 as a diagnostic or prognostic marker of tumour initiation; the use neto-2 polypeptides in the identification of agents that inhibit activity; and including antibodies that bind neto-2 and vaccines comprising neto-2 polypeptides.. .
| Fragment of secreted heat shock protein-90alpha (hsp90alpha) as vaccines or epitope for monoclonal antibody drugs or target for small molecule drugs against a range of solid human tumors|
The invention provides methods for treating hif-1α-overexpressing human tumors, inhibiting hif-1α-overexpressing tumor invasion and preventing tumor metastasis, and/or promoting tumor prophylaxis, using various types of inhibitors against the hsp90α from the tumors.. .
| Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof|
The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis b virus (hbv) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies.
The present invention relates to an n-glycosylated protein for treating and/or preventing bacterial pasteurellaceae infection in a mammal or bird, wherein the protein is a pasteurellaceae protein, a functional fragment or derivative thereof having at least one glycosylated n-x-s/t consensus sequence. In addition, the present invention is directed to corresponding pharmaceutical compositions for treating and/or protecting mammals or birds having or being prone to develop a bacterial pasteurellaceae infection.
|In situ antigen-generating cancer vaccine|
The invention provides compositions and methods for utilizing scaffolds in cancer vaccines.. .
|Therapeutic vaccines for treating herpes simplex virus type-2 infections|
The invention provides methods and kits for inducing a therapeutic immunity in animals (e.g. Mammals) against viral antigens, including herpes-simplex virus type 2.
|Stabilised vaccine composition|
The invention also extends to hiv vaccines comprising the same and use in treatment/prevention of hiv.. .
|Herpes virus vaccine and methods of use|
Provided herein are, inter alia, vaccines and methods of using the same for the treatment or prevention of herpesvirus infections.. .
|Vaccine composition containing synthetic adjuvant|
Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (gla) that is provided in substantially homogeneous form. Chemically defined, synthetic gla offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants.
The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease and to methods for the detection of such oligodeoxynucleotides.. .
The present invention relates to immunogenic compositions comprising 26 μg-45 μg of pneumolysin and/or phtd, vaccines comprising the immunogenic compositions and their use in medicine.. .
|Peptide carrier fusion proteins as allergy vaccines|
The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the n- and c-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide.. .
|Functional influenza virus-like particles (vlps)|
The present invention discloses and claims virus like particles (vlps) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising vlps of the inventions.
|Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same|
Compositions, recombinant vaccines and live alternated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes il-15ra or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed..
|Metal-citrate transporter antigen from streptomyces coelicolor and uses thereof|
The present invention relates to an isolated antigen from streptomyces coelicolor that is useful for developing, inter alia, vaccines against pathogenic bacteria of humans and animals. The present invention also relates to vaccines and antibodies developed using the isolated antigen.
|Oligosaccharides and oligosaccharide-protein conjugates derived from clostridium difficle polysaccaride ps-i, methods of synthesis and uses thereof, in particular as vaccines and diagnostic tools|
The invention relates to a synthetic oligosaccharide representing part of the repeating unit of the clostridium difficile glycopolymer ps-i and having the sequence of the pentasaccharide a-l-rhap-(1→3)-β-d-glcp-(1→4)-[a-l-rhap-(1→3]-a-d-glcp-(1→2)-a-d-glcp or a synthetic fragment or derivative thereof. Preferably, the claimed synthetic oligosaccharide bears at least one linker l for conjugation to a carrier protein or for immobilization on a surface.
|Novel immunogenic proteins of leptospira|
The invention provides novel immunogenic proteins liga and ligb from leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.. .
|Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy|
In one embodiment, a single modality cancer immunotherapy regimen that includes a therapeutic composition is provided. Such a therapeutic composition may include a salmonella strain comprising a plasmid that expresses an shrna molecule that suppresses the expression of an immunosuppressive target and suppresses tumor growth.
|Protein matrix vaccines and methods of making and administering such vaccines|
The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.. .
|Bacterial rnas as vaccine adjuvants|
The disclosure features vaccine adjuvants comprising prokaryotic mrna, and methods of vaccination using the adjuvants. More specifically, the disclosure provides a vaccine composition comprising a nonviable immunogen (e.g., heat-killed bacterium), a tumor antigen, or an immunogenic peptide of microbial or mammalian origin, and an adjuvant, wherein adjuvant comprises prokaryotic mrna (e.g., bacterial mrna), as well as the methods of using the vaccine compositions.
|Interferon-ß production modulating listeria strains and methods for using same|
Mutant listeria bacteria that modulate interferon-b production are provided. The subject bacteria are characterized by having a mutation in a gene chosen from a tetr gene, a ladr gene, a virr gene, a marr gene a mdrl gene, a mdrt gene and a mdrm gene.
|Method for producing protein-carbohydrate vaccines reduced in free carbohydrate|
This invention is directed to processes for reducing the level of free carbohydrate from a solution of protein-linked carbohydrate (conjugate) and non-linked carbohydrate. In this process, the conjugate is adsorbed to a hydrophobic membrane while the carbohydrate is not.
|Potomac horse fever isolates|
The present invention discloses novel isolates of neorickettsia risticii, compositions comprising such isolates, vaccines and methods for using such vaccines against potomac horse fever.. .
|Vaccines and methods for using the same|
Improved anti-hiv immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for hiv subtype a envelope protein, those having consensus sequences for hiv subtype b envelope protein, those having consensus sequences for hiv subtype c envelope protein, those having consensus sequences for hiv subtype d envelope protein, those having consensus sequences for hiv subtype b consensus nef-rev protein, and those having consensus sequences form hiv gag protein subtypes a, b, c and d.
|Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection|
The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding hcmv antigens, in which the naturally-occurring coding regions for the hcmv antigens have been modified for improved translation in human or other mammalian cells through codon optimization.
|Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides|
The present invention provides immunogenic peptides comprising the amino acid sequence of seq id no: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic t cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines..
|Thermo-electric heat pump systems|
This invention relates to providing energy efficient thermo-electric heat pump systems for iso-thermal transport and storage, of perishable goods, such as vaccines, chemicals, biologicals, and other temperature sensitive goods. Also this invention relates to providing energy efficient iso-thermal transport and storage systems, of perishable goods, which are compact, light weight.
Novel murine astroviruses, and methods of detecting the viruses are disclosed. Also disclosed are uses of the viruses and infected animals as model systems for discovery and development of vaccines and therapies for diseases caused by or associated with astrovirus infection, including human astrovirus-based diseases..
|Individualized vaccines for cancer|
The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a).
|Method for increasing etec cs6 antigen presentation on cell surface and products obtainable thereof|
A method for increasing the presentation of etec cs6 antigen on cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against cs6-expressing etec.
|Leptospira with increased antigenic mass|
The antigenic mass of leptospira cultures can be significantly increased, independent from any increase in biomass, by supplementing leptospira cultures with a specific fatty acid: linoleic acid. This provides advantages in the production leptospira antigens.
|Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines|
The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered with an adjuvant which adjuvant comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which adjuvant includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [c20: 5ω3], decosahexaenoic acid [c22: 6ω3], ricinoleic acid and derivatives thereof selected from the group consisting of the c1 to c6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide..
|Idna vaccines and methods for using the same|
Described herein are idna vectors and vaccines and methods for using the same. The idna generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic rna viruses, particularly yellow fever virus and venezuelan equine encephalitis virus.
|Vaccines including antigen from four strains of influenza virus|
Vaccines of the invention include at least four influenza virus strains. In some embodiments, the vaccines are produced in cell culture rather than in eggs.
|Total polysaccharides of radix isatidis and their fractions, and uses thereof as vaccine adjuvants|
The present invention pertains to medicinal technical field, relates to a radix isatidis total polysaccharide and fractions thereof and their uses as vaccine adjuvant. Specifically, it relates to a radix isatidis total polysaccharide as well as neutral polysaccharide fraction and acidic polysaccharide fraction extracted from chinese medicinal material radix isatidis, and to their uses as vaccine adjuvant or uses in manufacture of vaccine composition.
|Nucleic acid composition and methods of eliciting an immune response using the same|
The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins.
|Rabies glycoprotein virus-like particles (vlps)|
The present invention is generally related to virus-like particles (vlps) comprising rabies virus (rv) glycoproteins (g proteins) and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of rabies virus infection.. .
|Breast cancer vaccine|
Compositions and methods for immunization against human breast cancer are disclosed. A breast cancer vaccine comprises an immunogenic polypeptide comprising human α-lactalbumin..
|Sema5b peptides and vaccines including the same|
As discussed in detail herein, isolated epitope peptides derived from sema5b bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite hla binding and/or ctl inducibility of the original sequences.
|Modulating regulatory t cell activity via interleukin 35|
Methods for regulating t cell function in a subject, particularly regulatory t cell activity are provided. Methods of the invention include administering to a subject a therapeutically effective amount of an interleukin 35-specific binding agent, such as an antibody or small molecule inhibitor.
|Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity|
A novel form of rugged dsrna with a unique composition and physical characteristics was identified with high specificity of binding to tlr3, which conveys an important range of therapeutic opportunities. Unlike the previous known antiviral ampligen® (poly i, poly c12,u) the new and improved form (poly i, poly c30,u) has a reduced tendency to form branched dsrna which results in increased bioactivity due to an increased ability to bind tlr3 receptor.
|Attenuated mannheimia haemolytica vaccines and methods of making and use|
The present invention provides attenuated m. Haemolitica strains that elicit an immune response in animal against m.
|Bacillus anthracis htra-defective-derived vaccines|
The invention provides an isolated bacillus cereus sensu lato strain, selected from bacillus anthracis, bacillus cereus and bacillus thuringiensis, in which the htra gene or any part thereof is silenced, and vaccines comprising the same.. .
|Compositions and methods for assessing functional immunogenicity of parvovirus vaccines|
The present invention is directed to mutant parvovirus vp1 unique region polypeptides, compositions comprising such polypeptides, methods of making such compositions, as well as methods for identifying the likely presence of parvovirus-neutralizing antibodies, and methods for assessing the functional immunogenicity of parvovirus vaccines and measuring a correlate of efficacy to assess a treatment for parvovirus infection.. .
|Porcine parvovirus 5a, methods of use and vaccine|
The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5a (ppv5a) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus..
|Polychlorinated biphenyls and squalene-containing adjuvants|
When using squalene in a vaccine adjuvant, there is a possibility of contamination with polychlorinated biphenyls (pcbs). Environmental exposure to pcbs may adversely affect children's immune responses to routine vaccinations.
|Hiv incidence assays with high sensitivity and specificity|
The invention provides methods for manipulating the distribution of hiv gene sequences from a subject infected with hiv to classify whether the subject has been infected for more or less than a year. The methods are useful, for example, in determining whether prophylactic interventions such as vaccines or drug candidates are slowing the rate of transmission in a population..
|Vaccine adjuvant, vaccine composition and method for preparing a vaccine adjuvant|
The disclosure provides a vaccine adjuvant, including a polysaccharide derived from antrodia camphorata (also named antrodia cinnamomea or taiwanofungus camphoratus) fruiting body, wherein the molecular weight of the polysaccharide is greater than 100 k da. Furthermore, the polysaccharide is obtained by an extraction process, and the extraction process includes: (a) adding powder of the antrodia camphorata fruiting body into water to form a mixture; (b) heating the mixture under reflux; (c) after step (b), removing an insoluble matter from the mixture; (d) after step (c), adding ethanol into the mixture to perform a precipitating step and obtain a precipitate; and (e) performing an isolating step to the precipitate to obtain a fraction the molecular weight of which is greater than 100 k da of the precipitate..
|Staphylococcus aureus div1b for use as vaccine|
The invention relates to an antigenic polypeptide referred to as divib and variants thereof, vaccines and immunogenic compositions comprising said polypeptide and the use of the vaccines and/or immunogenic compositions in the treatment and prevention of microbial infections.. .
|Focused radiation for augmenting immune-based therapies against neoplasms|
An approach combining immune-based therapies with focused radiation, including stereotactic radiation, to treat cancers is disclosed. The use of focused radiation primes the immune system in a similar manner to vaccines to augment immune-based therapies and can counteract the suppressive effects of a tumor.
|Adeno-associated-virus rep sequences, vectors and viruses|
The invention provides adeno-associated virus (aav) replication (rep) sequences. In one embodiment, the invention provides nucleotide sequences encoding a chimeric protein, wherein the encoded chimeric protein contains a wild type aav rep inhibitory amino acid sequence, and wherein the nucleotide sequences contain a scrambled and/or deoptimized polynucleotide sequence encoding the wild type aav rep inhibitory amino acid sequence.
The present invention relates to molecular biology, molecular genetics, and bioprocessing. The embodiments provide for compositions and methods for producing a biological product, such as an immunogenic agent, in an embryonated egg by introducing into the egg a rna effector molecule capable of modulating expression of a target gene, wherein the modulation enhances production of the biological product in the egg.
|Duck embryonic derived stem cell lines for the production of viral vaccines|
The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the ebx® cell line derived from duck embryonic stem cells, for the production of viral vectors and viruses.
|Process for stabilizing an adjuvant containing vaccine composition|
The present invention relates to a process for stabilizing an adjuvant containing vaccine composition, an adjuvanted vaccine composition in dry form and in particular a process for stabilizing an influenza vaccine composition, particularly an adjuvanted influenza vaccine composition in dry form.. .
The present invention relates to preparations of substances in hydrophobic solvents in which they would not normally be soluble and to processes for obtaining these preparations. In particular, the invention relates to preparations of hydrophilic species in hydrophobic solvents such as oils.
|Identification of a west nile virus cd4 t cell epitope and use thereof|
Described herein is the identification and of a potent west nile virus (wnv) cd4 positive t cell epitope and its use for increasing the immunogenicity of heterologous flavivirus vaccines, such as dengue virus type 2 (denv-2) dna and virus-like particle (vlp) vaccines. Also described are methods for the identification of potent t cell epitopes to enhance immunogenicity of multivalent vaccines..
|Mphosph1 peptides and vaccines including the same|
As discussed in greater detail herein, isolated epitope peptides derived from mphosph1 bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned mphosph1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite ctl inducibility of the original sequences.
The present invention relates to replication-competent arteriviruses having a decreased dub/deisgylating activity due to a mutation in the plp2 domain of the non-structural protein nsp2, to their use as a medicament, their use as a vaccine and in prophylaxis, to vaccines comprising such arteriviruses and to arteriviral plp2-ubiquitin complexes.. .